US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

3.440 +0.020 (+0.58%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
These stocks are moving in today's pre-market session ↗
Via Chartmill
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
Via Investor Brand Network
News headline image
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
Via Investor Brand Network
News headline image
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
From Quantum BioPharma
Via GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)Advances Two-Pronged Approach to Neurological Health
Via Investor Brand Network
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
Via Investor Brand Network
BioMedNewsBreaks — Why Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
Via Investor Brand Network
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis
Via Investor Brand Network
News headline image
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
From NetworkNewsWire
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
From Quantum BioPharma Ltd.
Via GlobeNewswire
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
From Quantum BioPharma Ltd.
Via GlobeNewswire
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 Next >